nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprenolol—ADRB3—Monoamine GPCRs—DRD4—conduct disorder	0.0552	0.0552	CbGpPWpGaD
Alprenolol—ADRB3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0464	0.0464	CbGpPWpGaD
Alprenolol—HTR1A—Serotonin receptors—HTR2A—conduct disorder	0.0459	0.0459	CbGpPWpGaD
Alprenolol—ADRB3—Monoamine GPCRs—HTR2A—conduct disorder	0.036	0.036	CbGpPWpGaD
Alprenolol—ADRB3—G alpha (s) signalling events—CGA—conduct disorder	0.0342	0.0342	CbGpPWpGaD
Alprenolol—ADRB1—Monoamine GPCRs—DRD4—conduct disorder	0.0328	0.0328	CbGpPWpGaD
Alprenolol—ADRB2—Monoamine GPCRs—DRD4—conduct disorder	0.0321	0.0321	CbGpPWpGaD
Alprenolol—HTR1A—Monoamine GPCRs—DRD4—conduct disorder	0.0313	0.0313	CbGpPWpGaD
Alprenolol—ADRB3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0303	0.0303	CbGpPWpGaD
Alprenolol—ADRB1—Melatonin metabolism and effects—MAOA—conduct disorder	0.0291	0.0291	CbGpPWpGaD
Alprenolol—ADRB1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0275	0.0275	CbGpPWpGaD
Alprenolol—ADRB2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0269	0.0269	CbGpPWpGaD
Alprenolol—HTR1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0263	0.0263	CbGpPWpGaD
Alprenolol—ADRB1—Monoamine GPCRs—HTR2A—conduct disorder	0.0214	0.0214	CbGpPWpGaD
Alprenolol—ADRB2—Monoamine GPCRs—HTR2A—conduct disorder	0.0209	0.0209	CbGpPWpGaD
Alprenolol—HTR1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0204	0.0204	CbGpPWpGaD
Alprenolol—ADRB1—G alpha (s) signalling events—CGA—conduct disorder	0.0203	0.0203	CbGpPWpGaD
Alprenolol—ADRB2—G alpha (s) signalling events—CGA—conduct disorder	0.0198	0.0198	CbGpPWpGaD
Alprenolol—ADRB1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.018	0.018	CbGpPWpGaD
Alprenolol—ADRB2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0176	0.0176	CbGpPWpGaD
Alprenolol—HTR1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0172	0.0172	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0163	0.0163	CbGpPWpGaD
Alprenolol—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.0142	0.0142	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Other—DRD4—conduct disorder	0.0142	0.0142	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—CGA—conduct disorder	0.0124	0.0124	CbGpPWpGaD
Alprenolol—ADRB3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00967	0.00967	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00962	0.00962	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00946	0.00946	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Other—HTR2A—conduct disorder	0.00929	0.00929	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00925	0.00925	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00913	0.00913	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—CGA—conduct disorder	0.00737	0.00737	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00724	0.00724	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—CGA—conduct disorder	0.00721	0.00721	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—CGA—conduct disorder	0.00705	0.00705	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—CGA—conduct disorder	0.00701	0.00701	CbGpPWpGaD
Alprenolol—ADRB3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00695	0.00695	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—DRD4—conduct disorder	0.00695	0.00695	CbGpPWpGaD
Alprenolol—HTR1A—G alpha (i) signalling events—DRD4—conduct disorder	0.00652	0.00652	CbGpPWpGaD
Alprenolol—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00646	0.00646	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—CGA—conduct disorder	0.00637	0.00637	CbGpPWpGaD
Alprenolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00632	0.00632	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00619	0.00619	CbGpPWpGaD
Alprenolol—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00605	0.00605	CbGpPWpGaD
Alprenolol—ADRB3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00595	0.00595	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0059	0.0059	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00542	0.00542	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0053	0.0053	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00518	0.00518	CbGpPWpGaD
Alprenolol—ADRB3—GPCR ligand binding—HTR2A—conduct disorder	0.00453	0.00453	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—CGA—conduct disorder	0.00416	0.00416	CbGpPWpGaD
Alprenolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00413	0.00413	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—DRD4—conduct disorder	0.00413	0.00413	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—CGA—conduct disorder	0.00407	0.00407	CbGpPWpGaD
Alprenolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00404	0.00404	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—DRD4—conduct disorder	0.00404	0.00404	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—CGA—conduct disorder	0.00398	0.00398	CbGpPWpGaD
Alprenolol—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00395	0.00395	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—DRD4—conduct disorder	0.00395	0.00395	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—DRD4—conduct disorder	0.00393	0.00393	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—CGA—conduct disorder	0.00378	0.00378	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—CGA—conduct disorder	0.00376	0.00376	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—CGA—conduct disorder	0.0037	0.0037	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—CGA—conduct disorder	0.00362	0.00362	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—DRD4—conduct disorder	0.00357	0.00357	CbGpPWpGaD
Alprenolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00353	0.00353	CbGpPWpGaD
Alprenolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00346	0.00346	CbGpPWpGaD
Alprenolol—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00345	0.00345	CbGpPWpGaD
Alprenolol—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00343	0.00343	CbGpPWpGaD
Alprenolol—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00341	0.00341	CbGpPWpGaD
Alprenolol—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00338	0.00338	CbGpPWpGaD
Alprenolol—HTR1A—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00313	0.00313	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—WASF1—conduct disorder	0.00302	0.00302	CbGpPWpGaD
Alprenolol—ADRB1—GPCR ligand binding—HTR2A—conduct disorder	0.00269	0.00269	CbGpPWpGaD
Alprenolol—ADRB2—GPCR ligand binding—HTR2A—conduct disorder	0.00263	0.00263	CbGpPWpGaD
Alprenolol—HTR1A—GPCR ligand binding—HTR2A—conduct disorder	0.00257	0.00257	CbGpPWpGaD
Alprenolol—ADRB3—GPCR downstream signaling—HTR2A—conduct disorder	0.00256	0.00256	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—DRD4—conduct disorder	0.00233	0.00233	CbGpPWpGaD
Alprenolol—ADRB3—Signaling by GPCR—HTR2A—conduct disorder	0.00233	0.00233	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—DRD4—conduct disorder	0.00228	0.00228	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—CGA—conduct disorder	0.00223	0.00223	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—DRD4—conduct disorder	0.00223	0.00223	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—CGA—conduct disorder	0.00218	0.00218	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—CGA—conduct disorder	0.00214	0.00214	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—DRD4—conduct disorder	0.00212	0.00212	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—DRD4—conduct disorder	0.00211	0.00211	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—DRD4—conduct disorder	0.00207	0.00207	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—DRD4—conduct disorder	0.00202	0.00202	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—WASF1—conduct disorder	0.00179	0.00179	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—WASF1—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—WASF1—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Alprenolol—ADRB1—GPCR downstream signaling—HTR2A—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Alprenolol—ADRB2—GPCR downstream signaling—HTR2A—conduct disorder	0.00149	0.00149	CbGpPWpGaD
Alprenolol—HTR1A—GPCR downstream signaling—HTR2A—conduct disorder	0.00145	0.00145	CbGpPWpGaD
Alprenolol—ADRB1—Signaling by GPCR—HTR2A—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—HTR2A—conduct disorder	0.00137	0.00137	CbGpPWpGaD
Alprenolol—ADRB2—Signaling by GPCR—HTR2A—conduct disorder	0.00135	0.00135	CbGpPWpGaD
Alprenolol—HTR1A—Signaling by GPCR—HTR2A—conduct disorder	0.00132	0.00132	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—CGA—conduct disorder	0.00131	0.00131	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—DRD4—conduct disorder	0.00125	0.00125	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—DRD4—conduct disorder	0.00122	0.00122	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—DRD4—conduct disorder	0.0012	0.0012	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—HTR2A—conduct disorder	0.000816	0.000816	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—HTR2A—conduct disorder	0.000798	0.000798	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—HTR2A—conduct disorder	0.00078	0.00078	CbGpPWpGaD
Alprenolol—ADRB3—Signaling Pathways—EP300—conduct disorder	0.000728	0.000728	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—COMT—conduct disorder	0.000591	0.000591	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—MAOA—conduct disorder	0.000586	0.000586	CbGpPWpGaD
Alprenolol—ADRB1—Signaling Pathways—EP300—conduct disorder	0.000432	0.000432	CbGpPWpGaD
Alprenolol—ADRB2—Signaling Pathways—EP300—conduct disorder	0.000423	0.000423	CbGpPWpGaD
Alprenolol—HTR1A—Signaling Pathways—EP300—conduct disorder	0.000413	0.000413	CbGpPWpGaD
Alprenolol—CYP2D6—Metabolism—EP300—conduct disorder	0.000253	0.000253	CbGpPWpGaD
